
PD-L1 Immunotherapy Delayed Triple Negative Breast Cancer Progression
MUNICH— Immunotherapy with the anti programmed death ligand 1 (PD-L1) checkpoint inhibitor atezolizumab in combination with nab-paclitaxel chemotherapy prolonged progression-free survival (PFS) among
MUNICH— Immunotherapy with the anti programmed death ligand 1 (PD-L1) checkpoint inhibitor atezolizumab in combination with nab-paclitaxel chemotherapy prolonged progression-free survival (PFS) among patients with metastatic triple-negative breast cancer in the randomized phase three IMpassion130 trial reported at the 2018 annual congress of the European Society for Medical Oncology, ESMO.
https://www.nejm.org/doi/full/10.1056/NEJMoa1809615?query=featured_home
The experimental treatment also prolonged overall survival (OS) in patients who tested positive for PD-L1—the molecular target of atezolizumab.
Transformative
“For me this is practice-changing. This is a massive step. This is the first time—a clear improvement in overall survival, not just a marginal improvement. We see a transformative benefit of nearly ten months based on survival in the control group of only 15 months. So it’s more than a 50 per cent improvement in overall survival which is a very meaningful result for patients with this difficult-to-treat sub-type of breast cancer.”
So said first author of the IMpassion130 trial Peter Schmid MD PhD, Chair of Oncology at Barts Cancer Institute and Queen Mary University of London and Director of St. Bartholomew’s Breast Cancer Centre in London UK in conversation with the Audio Journal of Oncology.
Tags
Next in ESMO 2018
All 11 interviewsInterview 8 of 11

Genomically Targeted Therapy Delays Advanced Breast Cancer Progression
MUNICH—A combination of the phosphoinositide 3-kinase (PI3K) inhibitor alpelisib plus fulvestrant significantly extended progression free survival (PFS) compared to placebo plus fulvestr
Related Episodes

Marija Balic MD PhD, AACR 2026: Whole Exome Sequencing of ctDNA Informs Post-Neoadjuvant Therapy Options for Patients with Triple Negative Early Breast Cancer
Whole Exome Sequencing of ctDNA Informs Post-Neoadjuvant Therapy Options for Patients with Triple Negative Early Breast Cancer An interview with: Marija Balic MD PhD, Chief of Medical Breast Oncology,

Christian Singer MD: Neoadjuvant Olaparib Combination Beats Standard of Care in Patients with Homologous Recombination Deficient BRCA 1/2-Positive Triple-Negative Breast Cancer
Homologous Repair Deficient Triple Negative Breast Cancer Positive for BRCA1/2 Mutations Better with Neoadjuvant Olaparib + Carboplatin

Jacob Sands MD; ESMO 2026: Tarlatamab Bispecific Antibody Maintenance Therapy Prolongs Life for Patients with Extensive Stage Small Cell Lung Cancer
MADRID, Spain—Patients with extensive stage small cell lung cancer now have the green-light to add treatment with the bispecific antibody tarlatamab to their maintenance anti-PD-1 immunotherapy after first line chemo-immunotherapy induction. Results from the phase 3 DeLLphi-305 trial were reported at the 2026 Annual Congress of the European Society for Medical Oncology showing significantly improved overall and progression-free survival. Peter Goodwin spoke with study author Jacob Sands MD, Associate Chief of the Lowe Center for Thoracic Oncology at the Dana-Farber Cancer Institute, in Boston, USA, and Assistant Professor of Medicine at Harvard Medical School: